SRQ Labs is continuing research on the interaction of Alpha Lipoic Acid and human ALDH2 activity.
We note the existence of alcohol flushing supplements that include Alpha Lipoic Acid at dosages significantly smaller than what scientific studies suggest are necessary for increased human ALDH2 activity.
We refer to a 2013 study by the Department of Emergency at Qilu Hospital of Shandong University, Jinan, Shangdong, PR China.
In this study, researchers tested the effect of 600 mg of intravenous Alpha Lipoic Acid administered once a day for 5 days.
At 24 hours and 1 week after treatment, ALDH2 activity was significantly higher in the α-LA group than in the untreated group (P < 0.05), whereas the levels of 8-iso-PGF2α were significantly lower in the α-LA group than in the untreated group (all P < 0.05). Importantly, the decrease of 8-iso-PGF2α levels correlated with the increased ALDH2 activity at both 24 hours (r = 0.6234, P < 0.001) and 1 week after treatment (r = -0.3941, P = 0.0014). α-LA may ameliorate oxidative stress through up-regulating ALDH2 activity in patients with ACS.
According to the results, a positive effect on ALDH2 activity was recorded at an dosage of 600 mg applied intravenously.
It is noted that current alcohol flushing supplements use less than 100 mg and are deliver the Alpha Lipoic Acid orally or topically rather than via IV.
It is concluded that the dosages used by current supplements using Alpha Lipoic Acid are insufficient and further research and testing is required to determine the optimal daily oral dosage for increased ALDH2 activity.
Our research is ongoing and we shall publish our results shortly.